Apigenin alleviates doxorubicin‐induced myocardial pyroptosis by inhibiting glycogen synthase kinase‐3β in vitro and in vivo

Abstract

Apigenin, a natural flavonoid compound found in chamomile (Matricaia chamomilla L.) from the Asteraceae family, has been shown in our previous study to possess antimyocardial hypertrophy and anti‐cardiac fibrosis effects. However, its effects and mechanisms on the pyroptosis of cardiomyocytes induced by doxorubicin (DOX) are poorly understood. The objective of this study was to investigate the role of GSK‐3β and the effects of apigenin in DOX‐induced cardiotoxicity. H9c2 cells stimulated with DOX were treated with SB216763 and apigenin. Additionally, a mouse model of DOX‐induced cardiotoxicity was prepared and further treated with apigenin and SB216763 for 30 days. The findings revealed that treatment with SB216763 or apigenin resulted in a significant reduction in the levels of pyroptosis‐related factors. Furthermore, the phosphorylation of GSK‐3β was enhanced while the phosphorylation of nuclear factor‐kB (NF‐κB) p65 was reduced following treatment with either SB216763 or apigenin. Conversely, the effects of apigenin treatment were nullified in siRNA‐GSK‐3β‐transfected cells. Results from computer simulation and molecular docking analysis supported that apigenin could directly target the regulation of GSK‐3β. Therefore, our study confirmed that the inhibition of GSK‐3β and treatment with apigenin effectively suppressed the pyroptosis of cardiomyocytes in both DOX‐stimulated H9c2 cells and mice. These benefits may be attributed in part to the decrease in GSK‐3β expression and subsequent reduction in NF‐κB p65 activation. Overall, our findings revealed that the pharmacological targeting of GSK‐3β may offer a promising therapeutic approach for alleviating DOX‐induced cardiotoxicity.